Processa Pharmaceuticals (PCSA) Price to FCF (2014 - 2026)

Processa Pharmaceuticals (PCSA) has reported Price to FCF for 13 consecutive years, with 2.7 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to FCF fell 92.23% year-over-year to 2.7; the trailing twelve-month figure through Jun 2026 stood at 0.43 (down 46.17% YoY), and the FY2025 full-year result was 0.31, down 28.0% from the prior year.
• Price to FCF slipped to 2.7 in Q2 2026 per PCSA's latest filing, from 1.65 in the prior quarter.
• Across five years, Price to FCF topped out at 1.2 in Q4 2024 and bottomed at 26.44 in Q1 2022.
• Historically, Price to FCF has averaged 5.71 across 5 years, with a median of 3.1 in 2024.
• The sharpest annual moves came in 2022 and 2025: Price to FCF jumped 85.97% in 2022, then sank 133.44% in 2025.
• Over 5 years, Price to FCF stood at 7.06 in 2022, then surged by 42.56% to 4.06 in 2023, then jumped by 70.34% to 1.2 in 2024, then declined by 8.05% to 1.3 in 2025, then slumped by 107.64% to 2.7 in 2026.
• According to Business Quant data, Price to FCF over the past three periods registered 2.7, 1.65, and 1.3 for Q2 2026, Q1 2026, and Q4 2025 respectively.